Evushield will only be given to adults who are immunocompromised or taking immunosuppressive drugs, and those whose job puts them at risk of infection.

Data released by AstraZeneca last month showed that Evusheld reduces the risk of severe symptoms or death by 50% in COVID-19 patients.